Chelsea Counsel Company’s Medtronic MDT Stock Holding History

Chelsea Counsel Company’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.5K	Hold	500	–	–	0.02%	142
2026 Q1	$43.7K	Hold	500	–	–	0.02%	141
2025 Q4	$48.4K	Hold	500	–	–	0.02%	135
2025 Q3	$48K	Hold	500	–	–	0.02%	136
2025 Q2	$43.9K	Hold	500	–	–	0.02%	140
2025 Q1	$45.3K	Hold	500	–	–	0.02%	138
2024 Q4	$40.3K	Hold	500	–	–	0.02%	139
2024 Q3	$45.4K	Buy	+500	New	+$42.1K	0.02%	141

Other funds holding MDT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Chelsea Counsel Company's MDT Position: Q2 2026 in Review

Chelsea Counsel Company held its Medtronic (MDT) position steady in Q2 2026 at 500 shares worth $39.5K. The position accounts for 0.02% of the portfolio, ranked #142.

Chelsea Counsel Company first reported a position in MDT in Q3 2024 and has held it in 8 quarters since. The position peaked at $48.4K in Q4 2025. 2,140 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

Chelsea Counsel Company held 500 shares of Medtronic worth $39.5K as of Q2 2026.
Chelsea Counsel Company left its Medtronic share count unchanged in Q2 2026.
Medtronic made up 0.02% of Chelsea Counsel Company's portfolio in Q2 2026, its #142 holding.
Chelsea Counsel Company first reported a position in Medtronic in Q3 2024 and has held it in 8 quarters since.
Chelsea Counsel Company's Medtronic position peaked at $48.4K in Q4 2025.
2,140 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Chelsea Counsel Company's 13F filing for Q2 2026, filed 12 Aug 2026.